Donoghue Forlines LLC Blueprint Medicines Corp Transaction History

Donoghue Forlines LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 11, 2022	SELL	$94.25 - $115.99 $484,633 - $596,420	-5,142 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$80.98 - $109.47 $8,907 - $12,041	110 Added 2.19%	5,142 $529,000
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $12,499 - $15,251	151 Added 3.09%	5,032 $443,000
Q1 2021 May 14, 2021	BUY	$90.71 - $108.28 $94,791 - $113,152	1,045 Added 27.24%	4,881 $475,000
Q4 2020 Feb 09, 2021	BUY	$92.08 - $124.48 $353,218 - $477,505	3,836 New	3,836 $430,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Donoghue Forlines LLC, based on Form 13F filings with the SEC.

Stay updated on Donoghue Forlines LLC with notifications on news.